STOCK TITAN

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

I-Mab (NASDAQ: IMAB) announced it will release its Q3 2024 financial results on November 14, 2024, before the US market opens. The company will not hold a conference call for Q3 results but plans to host an investor update call with its full-year 2024 results, where it will discuss its clinical pipeline, corporate strategy, and objectives. Financial results and related information will be available on the company's website.

I-Mab (NASDAQ: IMAB) ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 il 14 novembre 2024, prima dell'apertura del mercato statunitense. L'azienda non terrà una conference call per i risultati del terzo trimestre, ma prevede di organizzare una chiamata di aggiornamento per gli investitori in occasione della pubblicazione dei risultati del 2024, durante la quale discuterà del suo pipeline clinico, della strategia aziendale e degli obiettivi. I risultati finanziari e le informazioni correlate saranno disponibili sul sito web dell'azienda.

I-Mab (NASDAQ: IMAB) anunció que publicará sus resultados financieros del tercer trimestre de 2024 el 14 de noviembre de 2024, antes de la apertura del mercado estadounidense. La empresa no llevará a cabo una llamada de conferencia para los resultados del tercer trimestre, pero planea organizar una llamada de actualización para inversores con los resultados del año completo de 2024, donde discutirá su pipeline clínico, estrategia corporativa y objetivos. Los resultados financieros y la información relacionada estarán disponibles en el sitio web de la empresa.

I-Mab (NASDAQ: IMAB)2024년 3분기 재무 결과를 2024년 11월 14일 미국 시장 개장 전에 발표할 것이라고 밝혔습니다. 회사는 3분기 결과에 대한 컨퍼런스 콜을 진행하지 않지만, 2024년 전체 연도 결과 발표와 함께 투자자 업데이트 콜을 주최할 계획입니다. 이 자리에서 임상 파이프라인, 기업 전략 및 목표에 대해 논의할 것입니다. 재무 결과 및 관련 정보는 회사 웹사이트에서 확인할 수 있습니다.

I-Mab (NASDAQ: IMAB) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 le 14 novembre 2024, avant l'ouverture du marché américain. L'entreprise ne tiendra pas de conférence téléphonique pour les résultats du troisième trimestre, mais prévoit d'organiser un appel de mise à jour pour les investisseurs avec ses résultats de l'année entière 2024, où elle discutera de son pipeline clinique, de sa stratégie d'entreprise et de ses objectifs. Les résultats financiers et les informations connexes seront disponibles sur le site web de l'entreprise.

I-Mab (NASDAQ: IMAB) hat bekannt gegeben, dass es seine Finanzergebnisse für das dritte Quartal 2024 am 14. November 2024, vor der Eröffnung des US-Marktes, veröffentlichen wird. Das Unternehmen wird keinen Konferenzanruf für die Ergebnisse des dritten Quartals abhalten, plant jedoch, einen Investoren-Updatesanruf mit den Ergebnissen des Gesamtjahres 2024 zu veranstalten, in dem es seine klinische Pipeline, Unternehmensstrategie und Ziele erörtern wird. Die Finanzergebnisse und verwandte Informationen werden auf der Unternehmenswebsite verfügbar sein.

Positive
  • None.
Negative
  • None.

ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time.

The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline, corporate strategy, and objectives. Information about financial results, conference calls, webcasts, and other information is posted on the Company's website.

About I-Mab

I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.

I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.

I-Mab Investor & Media Contacts
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-release-q3-2024-financial-results-on-november-14-2024-302292364.html

SOURCE I-Mab Biopharma

FAQ

When will I-Mab (IMAB) release its Q3 2024 financial results?

I-Mab will release its Q3 2024 financial results on Thursday, November 14, 2024, before the US market opens (pre-market Eastern Time).

Will I-Mab (IMAB) host a Q3 2024 earnings call?

No, I-Mab will not host a conference call to discuss Q3 2024 financial results. However, the company plans to host an investor update call with its full-year 2024 results.

What will I-Mab (IMAB) discuss in its upcoming full-year 2024 investor update call?

I-Mab plans to discuss its clinical pipeline, corporate strategy, and objectives during the full-year 2024 investor update call.

I-MAB American Depositary Shares

NASDAQ:IMAB

IMAB Rankings

IMAB Latest News

IMAB Stock Data

78.05M
62.25M
11.16%
30.88%
0.76%
Biotechnology
Healthcare
Link
United States of America
Rockville